Product image of Menjugate (N. Meningitidis Group C (Strain C11) Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm19) supplied by GNH India

Menjugate

Active Ingredient:
N. Meningitidis Group C (Strain C11) Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm19
Origin:
EU

Menjugate (N. Meningitidis Group C (Strain C11) Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm19)

N. meningitidis Group C (Strain C11) oligosaccharide conjugated to Corynebacterium diphtheriae CRM197, the active ingredient in Menjugate, is a vaccine presented as an injectable solution for intramuscular use. It prevents invasive disease caused by Neisseria meningitidis serogroup C in individuals at risk.

GNH India supplies Menjugate as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Gsk Vaccines S.R.L.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Menjugate is a conjugate vaccine that targets Neisseria meningitidis serogroup C to provide active immunity.

  • Invasive meningococcal disease (serogroup C): reduces the risk of meningitis and septicemia caused by the bacterium.
  • Outbreak control: helps limit the spread of serogroup C disease in community or institutional settings.
  • Travel to endemic regions: offers protection for travelers who may be exposed to serogroup C meningococcus.

How It Works

  • Menjugate contains the polysaccharide capsule of Neisseria meningitidis group C covalently linked to the diphtheria toxoid CRM197. This conjugation converts a T‑cell‑independent antigen into a T‑cell‑dependent form, prompting robust B‑cell activation and the production of high‑affinity, memory‑forming antibodies that neutralize the meningococcal capsule and prevent infection.

Side Effects

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness: localized erythema around the injection area.
  • Swelling: transient edema at the site of administration.
  • Fever: low‑grade temperature rise within 24‑48 hours.
  • Headache: mild headache following vaccination.
  • Malaise: general feeling of fatigue or unease.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Seizure: rare occurrence of convulsive activity post‑vaccination.
  • Guillain‑Barré syndrome: extremely rare autoimmune neuropathy.
  • Severe allergic reaction: includes angioedema or bronchospasm.
  • Immune‑mediated thrombocytopenia: very rare drop in platelet count.

Precautions & Warnings

Before administering Menjugate, consider the following precautions.

  • Allergy assessment: avoid in persons with known hypersensitivity to any vaccine component.
  • Pregnancy: use only if the expected benefit outweighs potential risk; consult a healthcare professional.
  • Immunocompromised patients: vaccine may be less effective; monitor immune response.
  • Concurrent vaccines: may be given with other vaccines at separate anatomical sites.
  • Age restrictions: approved for individuals meeting age criteria defined by local health authorities.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Menjugate may interact with other agents; monitor as indicated.

Major Interactions (Avoid)

  • Live bacterial vaccines: co‑administration may alter immune response.
  • Immunoglobulin therapy: can reduce vaccine efficacy.

Moderate Interactions (Monitor Closely)

  • Antipyretics: may mask post‑vaccination fever.
  • Immunosuppressive drugs: may diminish antibody production.
  • Blood products: may interfere with serologic testing for vaccine response.

Frequently Asked Questions

Menjugate is a conjugate vaccine indicated for the prevention of invasive disease caused by Neisseria meningitidis serogroup C, including meningitis and septicemia, in individuals who are at risk or require protection against this specific meningococcal strain.

The active ingredient combines the polysaccharide capsule of meningococcal group C with the diphtheria toxoid CRM197. This conjugation creates a T‑cell‑dependent antigen that stimulates robust antibody production and immunological memory, providing long‑lasting protection against the bacterium.

The dosing regimen for Menjugate is determined by the prescribing healthcare professional based on the patient’s age, health status, and local immunization guidelines. The prescriber will specify the exact dose and schedule.

Safety data for Menjugate in pregnancy are limited. It should only be administered when the potential benefit to the mother outweighs any possible risk to the fetus, and the decision should be made in consultation with a qualified healthcare provider. Breastfeeding considerations follow the same precautionary approach.

To place an order, submit an enquiry on the Menjugate product page at gnhindia.com, providing the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then replies with pricing, availability, cold‑chain shipping details, and necessary import documentation.

Menjugate is a group C conjugate vaccine, which offers a T‑cell‑dependent immune response and longer-lasting immunity compared with plain polysaccharide vaccines. It is specifically targeted at serogroup C, whereas some other licensed vaccines cover multiple serogroups (A, C, W, Y, or B) in a single formulation.

Menjugate must be stored refrigerated at 2‑8 °C. Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking the solution. Follow cold‑chain procedures during transport to maintain vaccine potency.

Menjugate is given as an intramuscular injection, typically into the deltoid muscle of the upper arm. The injection is performed by a qualified healthcare professional using aseptic technique, and the site should be observed for any immediate reactions.

The most serious adverse events reported with Menjugate include severe allergic reactions such as anaphylaxis, rare neurological conditions like Guillain‑Barré syndrome, and very uncommon immune‑mediated thrombocytopenia. Any signs of a serious reaction require immediate medical evaluation.

Menjugate should not be administered to individuals with a documented severe allergy to any component of the vaccine, including the diphtheria toxoid CRM197. Persons with a history of severe anaphylactic reactions to previous doses should also avoid further vaccination.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing N. Meningitidis Group C (Strain C11) Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm19

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT